As of June 2019, when F1CDx and ODxTT were launched, F1CDx had a companion diagnostic (CDx) function across cancer types, including NSCLC, which is a test for the use of approved drugs under insurance and a comprehensive genome profile (CGP) test function covering 324 genes, whereas ODxTT had only a CDx function for EGFR, ALK, ROS1, and BRAF [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.